In both studies, Vabysmo was found to be noninferior to aflibercept, with average vision gains being comparable between the treatment groups. The Food and Drug Administration (FDA) has approved ...

Following a second injection at eight weeks, the patient maintained stable vision and remained dry at 12 weeks, allowing for ...

The optic cup and macula of a 24-year-old female. Image is released to Wikimedia commons with patient consent. Imaged with a non-mydriatic fundus camera at Pacific University College of Optometry.

Resistant diabetic macular edema may necessitate transitioning from one intravitreal pharmacotherapy to another when the edema is persistent — a practice sometimes undertaken in clinical management.

(Nasdaq: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases, today announced the first patient dosed in ...

DME is a diabetes complication that threatens your the clarity of your vision. But managing blood sugar, blood pressure, and ...

Patients with nonischemic branch retinal vein occlusion had their macular edema severity associated with leakage index. Leakage index was found to have an association with macular edema severity in ...

Brolucizumab (Beovu) proved noninferior to aflibercept (Eylea) for visual outcomes among patients with diabetic macular edema (DME), the phase III KINGFISHER trial showed. In over 500 patients with ...